

CHAPTER III PERFORMANCE REVIEWS

This chapter contains performance reviews on ‘Implementation of Drugs and Cosmetics Act, 1940’, ‘Prevention and control of fire’, ‘National AIDS Control Programme’, ‘Functioning of Agriculture Department’, ‘Alimineti Madhava Reddy Project’ and ‘Information Technology Audit of computerisation in Forest Department’.

HEALTH, MEDICAL AND FAMILY WELFARE DEPARTMENT

3.1 Implementation of Drugs and Cosmetics Act, 1940

Highlights

The Drugs and Cosmetics Act 1940 (Act) is a Central Act to be implemented by all the States. The Act along with the other associated Acts and the rules made thereunder regulate the import, manufacture, distribution, sale and clinical research of drugs and cosmetics. In Andhra Pradesh the Drugs Control Administration (DCA) was functioning with only 55 Drugs Inspectors (DIs) for the last 10 years against the requirement of 240. Huge shortage of DIs adversely affected the functioning of the DCA and menace of spurious drugs continued to prevail. No follow-up action was taken to withdraw the drugs (from the market) declared as not of standard quality. The licensing system was ineffective and the DCA did not maintain proper record. Monitoring at State level was poor. Thus the objective of prevention of the menace of spurious drugs to eliminate the danger to human life had not been achieved.

❖ Eighty per cent (578) of the prosecution cases were pending trial in courts due to lack of administrative will.

[Paragraph 3.1.3 (i)]

❖ The shortfall in inspections of manufacture and sale units ranged from 15 to 67 per cent due to huge shortage (77 per cent) of Drugs Inspectors. There was no increase in the number of DIs during last 10 years.

[Paragraphs 3.1.4 II (i) and (iii)]

❖ Approval of Government on proposals of strengthening of Drugs Control Administration with the World Bank assistance submitted in 1997 was awaited.

[Paragraph 3.1.4 III]

The abbreviations used in this review are listed alphabetically in glossary vide Appendix XLIX (page 211)

❖ Due to lack of funds for payment of cost of samples, the targets fixed for analysis of drugs samples were not achieved; shortfall ranged from 4 to 21 per cent.

[Paragraphs 3.1.4 II (ii) and IV (i)]

❖ Out of 18493 samples analysed there were delays of over three months in 1588 samples. Analysis of 1807 samples was not completed, of which life of 57 samples had expired.

[Paragraph 3.1.4 IV (ii)]

❖ Though 832 samples were declared as not of standard quality (NSQ), no follow-up action was taken by the Drugs Inspectors/ DCA to ensure withdrawal of these drugs from the market.

[Paragraph 3.1.4 V]

❖ The Legal-cum-Intelligence Cell and Anti-spurious drugs squads were not established.

[Paragraph 3.1.4 VII]

❖ Information, Education and Communication (IEC) activities were not undertaken. The DCA had not developed any database of manufacturers/sale concerns/ licences/ management information system and monitoring system modules for drug control functions.

[Paragraphs 3.1.4 VIII and 3.1.7]

❖ Inspection of Indian Medicine units had not been conducted except at the time of sanction of fresh licences. Shortfall in respect of Homoeopathic units was between 92 and 98 per cent.

[Paragraph 3.1.5 (i)]

❖ Training of DIs and other staff was altogether neglected and no training programmes were organised by the ADG, DCA.

[Paragraph 3.1.6]

❖ There was no proper monitoring at State level on the implementation of the Act and Rules in the State.

[Paragraph 3.1.7]

3.1.1 Introduction

i) Background: At the beginning of the twentieth century, pharmaceuticals were being imported from abroad. After the First World War, manufacturing concerns, both Indian and Foreign, sprang up to produce pharmaceuticals at cheaper rates to compete with imported products. Some of these products were of inferior quality and harmful. Government, therefore, decided to introduce legislation to control the manufacture, distribution and sale of drugs and medicines. A Select Committee appointed by the Central Legislative Assembly in 1937 recommended various measures, providing for the uniform control of manufacture and distribution of

drugs as well as of import and finally the Drugs Act¹ was enacted on 10 April 1940.

At present, the Acts and Rules, apart from the Drugs and Cosmetics Act, 1940, which govern the manufacture, sale, import, export and clinical research of drugs and cosmetics in India are : The Pharmacy Act, 1948; The Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954; The Narcotics Drugs and Psychotropic Substances Act, 1985; The Medicinal and Toilet Preparations (Excise Duties) Act, 1956; The Drugs (Prices Control) Order 1995 (Under the Essential Commodities Act). However, ‘The Drugs and Cosmetics Act, 1940’ continues to be the main Act.

ii) Main features of the Act

- To ensure standards of Drugs and Cosmetics, Diagnostics and Devices.
- To monitor quality of drugs and medicines imported, manufactured, distributed and sold.
- To take punitive measures for violation of provisions of the Act.
- To regulate clinical research and publication of Indian Pharmacopoeia.

iii) Statutory functions: This is a Central Act and is applicable to all the States. Central Government lays down the regulatory measures and the standards of drugs, cosmetics and diagnostics, and makes amendments to Acts and Rules. It regulates market authorisation of new drugs and standards of imported drugs. It is the Central Licence Approving Authority for Blood Banks, Large Volume Parenterals and Vaccines and Sera. Drugs Technical Advisory Board (DTAB), Drugs Consultative Committee (DCC) and Central Drugs Laboratories are under the control of the Central Government.

The main functions of the State Government are (a) licensing of drug manufacturing and sales units, (b) licensing of drug testing laboratories, (c) approval of drug formulations for manufacture, (d) monitoring of quality of Drugs and Cosmetics manufactured, (e) investigation and prosecution in respect of contravention of legal provisions, (f) regulation of the standards of imported drugs, (g) inspection and (h) recall of sub-standard drugs.

A review on the implementation of Drugs and Cosmetics Act 1940 and other related Acts and Rules thereunder was conducted by test-check of the records for the period 1998-2003 at the office of the Additional Director General, Drugs and Copyright, Drugs Control Administration (ADG, DCA), six Assistant Directors (ADs),

¹ Drugs Act, 1940 was amended in December 1961 to provide for regulation of the manufacture of cosmetics and prohibition of import and sale of sub-standard and misbranded cosmetics

15 Drugs Inspectors (DIs), two Drugs Control Laboratories (DCLs) and the Commissioner of Indian Medicine and Homoeopathy covering nine districts and a population of 3.38 crore (44.6 per cent). The results of the review are mentioned in the succeeding paragraphs.

3.1.2 Implementation arrangements

The Principal Secretary to Government, Health, Medical and Family Welfare Department is responsible for implementation of the Act and the Rules at Government level. The ADG, DCA is the regulatory authority for allopathic drugs and cosmetics and is assisted by a Director, supported by two Joint Directors and other enforcement staff. The Organisational chart is given in *Appendix XXV*.

In regard to Ayurveda and other systems of medicines, the Commissioner of Indian Medicine and Homoeopathy is the head of the department and is assisted by three² Additional Directors³ and six⁴ Medical Officers posted as DIs.

Budget provision vis-à-vis the expenditure of the DCA during 1998-2003 was as follows.

(Rupees in crore)

Year	Budget estimates projected by DCA	Budget provision	Expenditure	Expenditure on salaries (percentage)	Expenditure on Travelling Allowances (percentage)
1998-99	2.82	2.61	2.80	2.39 (85)	0.06 (2)
1999-2000	3.08	3.18	3.29	2.94 (89)	0.06 (2)
2000-01	4.25	3.68	4.26	3.42 (80)	0.11(2)
2001-02	4.17	4.00	4.09	3.48 (85)	0.12 (3)
2002-03	4.91	4.56	4.13	3.57 (86)	0.08 (2)
Total		18.03	18.57	15.80 (85)	0.43 (2)

Incidence on TA was meagre 2 per cent

Though the main activity of the department requires enforcement staff to travel across the State to inspect the drugs manufacturing and sale units, meagre expenditure on travelling allowance was indicative of inadequate and ineffective coverage of inspections.

3.1.3 Enforcement

i) Standing of the Law – violation of provisions of Act/Poor progress in prosecution cases: Drugs and Cosmetics Act envisages that no person shall himself or by any other person on his behalf manufacture for sale or for distribution or sell or exhibit or offer for sale or distribute, any drug or cosmetic which is not of standard quality or is misbranded, adulterated or spurious.

² one for each system of medicine (Ayurveda, Unani & Homoeopathy)

³ not exclusively for implementation of the Act

⁴ 3 Ayurveda, 2 Unani, 1 Homoeopathy

578 prosecution cases (80 per cent) were pending trial in courts

During 1998-2003, out of 19017 violations reported, 492 charge sheets (three per cent) were filed in the Courts. Of these, 182 cases were filed in Vijayawada region during 2002-03, which included 55 cases of seizures of ayurvedic drug containing 'Sildenafil Citrate' (Para 3.1.4 VI (ii) refers). Out of the total 721 prosecution cases as of March 2003 (including 229 cases prior to 1998-99) 578 cases (80 per cent) were pending trial in courts for various reasons viz., (i) non-serving of summons (eight) by the Drug Inspectors and non-bailable warrants (23) of the offenders through police, (ii) absence of parties involved in the court at the time of hearing, etc. Of 143 cases decided in the courts during the period 115 were convicted. In 28 cases, the accused were acquitted mainly due to (i) failure to prove that the drugs seized were stocked for sale purpose; (ii) failure to produce two independent local mediators/witnesses; (iii) non-furnishing of drugs samples and analysis profile to the accused; (iv) delay in filing the complaint in the court; (v) contradictory evidence by the officials of enforcing authority in securing panch witnesses; and (vi) failure to prove the basic fact of inspection of place of detection of violation. Out of 38 conviction cases decided during 2002-03, fines of Rs 1000 and Rs 5000 was imposed in two cases and in other cases (36) both imprisonment (one month to five years) and fines (Rs 500 to Rs 20000) were awarded by courts.

Thus, lack of administrative will on the part of the enforcing authority and non-adherence of mandatory provisions of the Act led to the failure of prosecutions, despite the recommendations of Public Accounts Committee (March 2001) to take effective steps to launch the prosecutions without loss of time and to avoid lapses in prosecution to ensure that the offenders get due punishment.

Of 861 cases of violation during 1995-2003, 417 cases (48 per cent) were still under investigation with DCA

ii) Drugs (Price control) Order, 1995 and Drugs and Magic Remedies (Objectionable Advertisements) Act 1954: (a) As per the Drugs (Price Control) Order 1995, no person shall sell a bulk drug/formulation at a price exceeding the maximum sale price fixed by National Pharmaceutical Pricing Authority (NPPA), a body authorised by GOI. Under the Act, 861 cases of violation⁵ were detected during 1995-2003 (up to March 2003). Of these, the ADG, DCA filed charge sheets only in 85 cases (10 per cent), 156 cases (18 per cent) being sub-judice were kept in abeyance and 417 cases (48 per cent) were under investigation as of September 2003. It was noticed that particulars of violation cases (802) detected during 1995-2002 were sent to NPPA only in September 2002 due to delay in receipt of GOI orders on the representation of Drug Manufacturers Association.

56 out of 140 cases of violations (40 per cent) were still under investigations with DCA

(b) As per the provisions of Drugs and Magic Remedies (Objectionable Advertisement) Act, 1954, no person shall take part

⁵ 1995 : 8, 1996 : 481, 1997 : 134, 1998 : 37, 1999 : 9, 2000 : 32, 2001 : 101, 2002 : 59

in advertising any matter which (i) directly or indirectly gives a false impression regarding the true character of drug (ii) make false claim of the drug or (iii) misleading in any material particular. During 1993-2003, 140⁶ cases of violations of the Act were detected. Of these, complaints were filed in the courts in 66 cases (47 per cent) and conviction orders were issued only in 28 cases; 56 cases were under investigation with the DCA as of September 2003.

The delay in investigation of the cases could only result in the drugs continuing to be sold at higher rates/illegal sale of drugs.

3.1.4 Implementation of the Act - Allopathic medicines and Cosmetics

I Survey and licensing functions

No surveys of spurious drugs manufacture/distribution were conducted by DCA

Surveys were to be conducted at regular intervals to have the full information on the manufacture and sale of drugs in the market. Watchers/decoy customers were to be engaged for purchasing samples of drugs and to keep watch over the movement of suspected drugs especially at sensitive market places which were suspected to have manufacturers/distributors of spurious or doubtful quality of drugs by providing secret funds for such activity. DCA had not undertaken any such activity for want of such funds. As such, the manufacture and sale of spurious drugs continued to prevail in the market as evident from the NSQ drugs detected during 2002-03.

No record maintained to verify the current status of the grant of renewal of licence

i) Non-maintenance of licensing records: As per the Act the licences granted/renewed up to August 2001 was valid up to the end of the following calendar year in which the licence/renewal was granted. Since September 2001 the validity period was five years from the date of issue of licence/renewal.

The ADG, DCA however, did not maintain the records showing the total number of manufacture/sale units, the number of units applied for renewal, renewals sanctioned and units not applied for renewals. Separate records for fresh licences and renewals were maintained but no cross-linking of these records was done. In the absence of such data, the current status of the units and those not applied for renewals could not be established.

Scrutiny of the records of licensing pertaining to the year 1998 revealed that, out of 244 manufacturing units for which fresh licences were issued, subsequent renewals were made only in respect of 88 units, and 156 units (64 per cent) had not renewed their licences. No records were available with ADG, DCA to ensure that the enforcing authorities (DIs) have inspected such units after expiry

⁶ 10 cases pertained to the period 1993-98

of licence, to curb the any possible illegal manufacturing activity/manufacture of spurious drugs.

No mechanism to ensure compliance of stop production orders

Based on NSQ reports, Director, DCA ordered to stop production in 370 units and cancelled the licences of 198 units during 1998-2003. The DCA could not furnish the information with regard to the mechanism to ensure compliance of their orders.

Loss of revenues of Rs 5.72 lakh towards fees for fresh licences and renewals

ii) Short payment of licence fee: (a) The licence fee for both fresh licences and renewals in respect of manufacturing units was revised with effect from 24 August 2001. For each additional product Rs 300 was to be paid by the manufacturer. It was, however, noticed that the licence fee for additional products (i.e., in excess of 10 products) was not paid by 31 manufacturing units which applied for renewal during 2001 and 2002 resulting in a short payment of Rs 2.94 lakh.

(b) With effect from 24 August 2001 licence fee for distribution/sale of drugs and cosmetics was raised to Rs 3000 for a period of five years from Rs 80 for two calendar years. It was however noticed that the ADs, Cuddapah, Warangal, Vijayawada and Rajahmundry collected the licence fee at the old rate of Rs 80 from 235 applicants who applied for renewals between 24 August 2001 and 31 October 2001. This resulted in short realisation of Rs 2.78 lakh for two years. The ADs stated that Government notification was not communicated by ADG, DCA till November 2001.

The total loss of revenue in these cases amounted to Rs 5.72 lakh.

II Adequacy of sampling and inspection

Shortfalls in inspections ranged from 15 to 67 per cent

i) Shortfall in inspections: (a) As per the provisions of the Act and Rules, Drugs Inspectors (DIs) were required to inspect the manufacturing and sale units of drugs and cosmetics twice in a year up to 25 April 2001 and once in a year from 26 April 2001 to ensure compliance of conditions of licence, etc. and also to draw drug samples for quality test. There were shortfalls in inspection ranging from 15 to 67 per cent as detailed below:

Year	Number of Licensed units		Number of inspections		Shortfall in inspections (percentage)
	Manufacturing	Sale	to be conducted	Conducted	
1998-99	1993	32265	68516	23399	45117 (66)
1999-2000	2204	34815	74038	24569	49469 (67)
2000-01	1612	28319	59862	24729	35133 (59)
2001-02	1854	31348	33202	23367	9835 (30)
2002-03	1977	30726	32703	27836	4867 (15)

The shortfall led to inadequate check on the Good Manufacturing Practices to be followed by the manufacturers. The ADG, DCA did

not maintain any record to ensure inspections of all the manufacturing/sale units over a specified period.

The Director attributed (January 2003) the shortfall in inspections to shortage of DIs. Thus, due to short-coverage of inspection the menace of spurious drugs could not be arrested as discussed in succeeding paragraphs.

Shortfall in inspections was more than 50 per cent in Cuddapah, Vijayawada and Rajahmundry regions

(b) Shortfall in inspection in 21 DIs (test-checked 15 DIs and six DIs attached to ADs) ranged from 22 per cent (Nizamabad) to 72 per cent (Kakinada) in 1999-2000 and 2000-01 (*Appendix XXVI* refers). The shortfall in Cuddapah, Vijayawada and Rajahmundry regions was more than 50 per cent in all the years up to 2000-01. Further, there were large variations between the figures of units/inspections conducted as furnished by the six ADs and those furnished by the Directorate (*Appendix XXVII* refers). The reasons for variations were not explained by the Director.

ii) **Shortfall in lifting of drugs samples:** In order to ensure the quality of drugs manufactured and sold, the DIs are required to draw samples from manufacturing, distribution and sale units including hospitals for sending them to DCL for analysis. No methodology was evolved by the Department to ensure coverage of all the manufacturing and distribution units in a year. As per the targets⁷ fixed by the Department each DI was to collect at least six samples per month (eight from April 2002).

Scrutiny of the records of DIs revealed that two to four drugs samples were collected from a single unit to achieve the targets by covering less number of units. Nevertheless, the targets were not achieved by the DIs during 1998-2003, as shown below.

Year	Number of samples		Shortfall (percentage)
	to be drawn	Drawn	
1998-99	3960	3377	583 (15)
1999-2000	3960	3467	493 (12)
2000-01	3960	3976	--
2001-02	3960	3900	60 (2)
2002-03	5280	4706	574 (11)

No criteria adopted in regard to lifting of samples for analysis and drugs samples of general in nature concentrated/other samples ignored

The Director attributed (March 2003) the shortfall to vacancies in the cadre of DIs as also the inadequacy of budget provision for payment of cost of samples drawn. No criteria was adopted by the Department in regard to lifting of samples for analysis of various categories/types of drugs such as bulk drugs, formulations⁸. Thus, priority was not given to lifting samples of life saving drugs, antibiotics and other essential drugs, required for treatment of diseases like Cancer, TB, Cardio-Vascular, Renal etc. This led to

⁷ no basis for fixation of these targets

⁸ parenterals, ointments, syrups, tablets, surgical dressings, etc.

concentration on lifting drug samples, such as Paracetamol, Ibuprofen, B.Complex, Diclofenac Sodium etc. which were general in nature repeatedly while other essential drugs were ignored due to non-availability of sufficient funds for procurement of costly drugs.

Only 55 DIs were in place against 240 required. No increase in staff for the last 10 years

iii) Non-observance of staffing pattern: As per the recommendations of Hathi Committee (1975) and House Committee (1991), there should be one DI for every 25 manufacturing units and for every 200 sale units. The pattern of enforcement staff and analytical staff should be in the ratio of 1:1. There were 1977 manufacturing and 30726 sales units in the State as of March 2003, and to inspect these units 240 DIs and equal number of Junior Analysts were required for efficient functioning of the department. Against these, only 55 DIs (three vacant) and 25 Junior Analysts (seven vacant) were available; shortage being 77 per cent and 90 per cent respectively. There was no increase in number of staff for the last 10 years. Despite the PAC (2000-01) recommendation⁹ to place the enforcement staff to the required strength, no action was taken by Government to improve the position.

Though the ADG attributed the shortfall in inspections, lifting of samples and their analysis and other statutory functions mainly to the shortage of DIs, the ADG did not effectively pursue¹⁰ this key aspect with the Government. This adversely affected the prevention of spurious drug activity in the State endangering the health of public at large.

III Working of Drugs Testing Laboratories

Proposal of strengthening of Drugs Control Administration awaiting Government's approval

A proposal for strengthening of Enforcement Staff and augmentation of analytical testing facilities under World Bank assisted capacity building project (100 per cent Central assistance) were submitted by ADG, DCA to Government in March 1997. The proposal included augmentation of drug testing facilities, strengthening of Drugs Inspectors, construction/expansion of DCL buildings, purchase of vehicles and Laboratory equipment, etc. at an estimated cost of Rs 6.83 crore. Approval of the Government was not accorded as of September 2003. As a result, there was no improvement in all statutory functions of the Department.

IV Testing of drugs samples

Targets for testing of drugs samples not achieved

i) Shortfall in analysis of drugs samples: Analysis of drugs samples play an important role in determination of standards prescribed, prevention of consumption of sub-standard, adulterated

⁹ in its VI Report of XI Legislative Assembly

¹⁰ ADG submitted proposal in May 1997, but reminded Government only in April 2001, November 2002 and February 2003

and spurious drugs. GOI fixed annual target of 5000 drugs samples for analysis in the State. As against this, the Department fixed (1996-97) a target of 15 samples per month for analysis for each Junior Analyst i.e., 4500 samples per year. It was, however, observed that even the available samples were not analysed during 1998-2000 though these were less than targets fixed and these targets were not achieved during 2001-03 as detailed below.

Shortfall in analysis of samples was 4 to 21 per cent

Year	Number of samples				Shortfall (percentage)
	Opening balance	Received	Total	Analysed	
1998-99	874	3377	4251	4088	163 (4)
1999-2000	163	3467	3630	3275	355 (10)
2000-01	355	3976	4331	3588	743 (17)
2001-02	743	3900	4643	3566	934 (21)
2002-03	1077	4706	5783	3976	524 (12)

Note: Number of samples to be analysed during each year is 4500

Delays in testing of samples ranged up to three months

ii) Delay in testing of samples: No time limit was prescribed in the Act/Rules for analysis of drugs samples. However, as per the recommendations of the House Committee of the State (1991), the drugs samples should be analysed within two months. It was however, noticed that out of 18493 samples analysed during the period 1998-2003 there were delays of over one to three months in respect of 2980 cases (16 per cent) and over three months in 1588 cases (nine per cent). Analysis of 1807 samples (10 per cent) received during 1997-2003 was not completed as of March 2003, of which life of 57 samples had expired. The delay in analysing the drugs samples defeated the very purpose of prevention of sub-standard drugs sold in the market. The ADG, DCA attributed (December 2002) the delay to inadequate staff and testing facilities.

V Lack of adequate follow-up action on substandard drugs

Follow-up action not taken to ensure withdrawal of sub-standard drugs from market

Out of the 18493 samples analysed in the Laboratories at Hyderabad (15560) and Vijayawada (2933), 832 samples¹¹ were declared as not of standard quality (NSQ). No follow-up action was taken by the DIs/DCA, to ensure withdrawal of sub-standard drugs from the market.

VI Searches and Seizures

48 per cent cases of NSQ drugs were under investigation of DCA since 1998

i) Delay in finalisation/investigation of cases: As per the Act, no person shall manufacture for sale/distribution/stock/exhibit/offer for sale, any drug which is sub-standard quality/mis-branded/spurious, except in accordance with the conditions¹² of licence

¹¹ Hyderabad (759), Vijayawada (73)

¹² such as to manufacture under the supervision of competent technical staff, to follow and comply with the schedule 'M' and should contain therapeutic justification for ingredients, etc.

granted. During 1998-2003, ADG carried out 225 seizures¹³ suspected to be spurious/mis-branded, and detected 832 cases¹⁴ (Para 3.1.4 (V) also refers) of NSQ drugs. Of these, 399 cases (48 per cent) were under investigation as of March 2003; 87 cases were more than three years old. This indicated slackness of the DCA in completion of investigation and filing the complaints in the court; attributable to non-provision of any time limit in the Act/Rules.

55 out of 62 samples analysed contained Sildanafil Citrate

ii) *Seizure of Ayurvedic drug containing Sildanafil Citrate:* Based on a press news, the DIs conducted (September 2002) surprise check on a manufacturing firm¹⁵ and distribution/sale units and lifted 62 samples of Ozomen and Ozomen forte (Ayurvedic drugs) suspected to be containing "Sildanafil citrate" an allopathic drug. The firm had no licence for mixing 'Sildanafil Citrate' with the Ayurvedic drug. The samples were sent (September 2002) to DCL for analysis and the stock available (value : Rs 63.33 lakh) was also seized. Out of 62 samples analysed 55 samples contained Sildanafil citrate (Para 3.1.3 (i) refers). The case was still under investigation by the ADG, DCA (September 2003).

Gauze cloth, Roller Bandages were never lifted for analysis

iii) *Manufacture of gauze cloth, roller bandages by un-licensed manufacturers:* As per the provisions of Act, gauze cloth, roller bandages, bandage cloth are termed as drugs. Though the DIs lifted the drug samples from Government Hospitals and Institutions these items were never lifted for analysis evidently as no criteria was laid down for lifting of samples of drugs of different categories for analysis (Para 3.1.4 II (ii) refers). The materials were not seized though the labels of materials did not contain the particulars of licence granted for its manufacture. During the investigation, Anti Corruption Bureau (ACB), noticed (March 2001) that out of 58 firms who manufactured and supplied these items to Medical and Health Department during 1998-2000, 44 firms did not possess the drug licence. Government blacklisted (December 2001) 55 firms involved in manufacture of surgical dressing items such as gauze cloth, bandage cloth, roller bandages etc., under the provisions of the Act. The aggrieved firms approached the Hon'ble High Court and the Court issued interim orders (April 2002) suspending the Government Orders.

iv) *Seizure of Viagra and Bethanecol drugs:* In September 2002 DI, Uppal¹⁶ conducted surprise check at the premises of a firm whose licence was not renewed after December 1999. Certain drugs such as Sildnafil citrate caps, Viagra, Bethanecol tablets, Cifro floxicin, Acezoxforte and other material worth Rs 50 lakh, were

¹³ 1998-99 : 47, 1999-2000 : 34, 2000-01 : 46, 2001-02 : 39, 2002-03 : 59

¹⁴ 1998-99 : 191, 1999-2000 : 162, 2000-01 : 179, 2001-02 : 151, 2002-03 : 149

¹⁵ Fizikem Laboratories, Vijayawada

¹⁶ RangaReddy District

seized as these were suspected to be spurious and misbranded. The case was still under investigation by ADG, DCA and charge sheet not filed as of September 2003.

VII Non-establishment of Intelligence-cum-Legal branch/ Task Force Cells

Legal-cum-Intelligence Cell not formed/Anti-spurious drugs squads not established

The Legal-cum-Intelligence cell was not formed (September 2003) though recommended by the Hathi Committee (1975), and the police help was not taken during the departmental raids and also in tackling the spurious drug cases.

The Department had not also established any anti-spurious drugs squads, except formation of a task force cell in January 2003 with the existing staff under the supervision of a Joint Director who was entrusted with the co-ordination, conduct of seizures and searches and detection of violation of the Act. In the absence of independent task force cell the spurious drugs activity continued to prevail.

VIII Information, Education and Communication (IEC) activities not undertaken

IEC activity altogether neglected

Though active participation of enforcement agencies, pharma industry, trade and consumers and common public, etc. was necessary to combat the menace of spurious and sub-standard drugs activity, the ADG, DCA had not undertaken any IEC activities during 1998-2003 statedly due to budget constraints. This was not tenable as no proposals were sent by him for budget allotment under IEC.

Communication network not established either within the State or with other States

The DCA had not created any communication network within the State, with other States and with other departments for dissemination and sharing of information on movement of spurious drugs and persons involved in such activity.

3.1.5 Ayurvedic and other systems of medicines

No separate budget provision was made for implementation of the Act by Indian Medicine and Homoeopathy Department. Expenditure of Rs 19 lakh to Rs 23 lakh, was incurred every year during 1998-2003. The following points were noticed in audit.

DIs had not conducted any inspection of Ayurvedic and Unani units

i) Non-conducting of inspections of Manufacturing units:
(a) As per the Act the DIs (Ayurvedic and Unani) were required to inspect the premises licensed for manufacture of Ayurvedic and Unani drugs twice a year.

Scrutiny revealed that the DIs had not conducted any inspection during 1998-2003, except at the time of sanction of fresh licence to the units (ranging from 484 to 656), statedly due to shortage of staff.

**Heavy shortfall
(92 to 98 per cent)
in inspections of
units of
Homoeopathic
drugs**

(b) Shortfall in inspection of the manufacturing and sale units of Homoeopathic drugs were as follows:

Year	Number of		Number of inspections		Shortfall (percentage)
	Manufacturing units	sale units	to be conducted	conducted	
1998-99	35	325	720	11	709 (98)
1999-2000	39	307	692	35	657 (95)
2000-01	40	231	542	15	527 (97)
2001-02	38	170	208	17	191 (92)
2002-03	39	175	214	14	200 (93)

The Commissioner attributed (December 2002) the shortfalls to shortage of staff and funds. Due to huge shortfall in inspection, possibility of spurious drug activities could not be ruled out.

ii) Short collection/Delay in analysis of drug samples: As per the Act, the DIs were required to inspect the manufacturing units and collect the drugs samples for quality test. The department has not fixed any targets for lifting samples of Ayurvedic and Unani drugs for analysis. During 1998-2002, only 19 samples of Ayurvedic drugs were collected. In 2002-03, out of 47 samples collected 11 were not analysed. During 1998-2003, only 11 samples of Unani drugs were collected, of which nine samples collected during 1999-2001 were not analysed. Reasons for poor lifting of samples were not explained by the Commissioner. Though non-analysis of samples was attributed (December 2002) to non-availability of chemicals, ingredients and methods of testing in the Drug Testing Laboratory for want of funds; separate budget provision was not sought for the laboratory needs by the Commissioner.

iii) Drug Testing Laboratory not strengthened: The Drug Testing Laboratory (DTL), Katedan, Hyderabad conducts analysis of raw material and finished Ayurvedic Medicines of Government Indian Medicine Pharmacy (Ayurveda), Katedan. Samples of Ayurveda and Unani drugs were also taken up for analysis depending upon the feasibility at the laboratory, as the samples were of patent in nature and did not have proven method of analysis as there is no prescribed pharmacopoeia¹⁷ for ayurvedic drugs.

**Drugs Testing
Laboratory
(Ayurvedic) not
strengthened
despite the
availability of
Central assistance**

For strengthening the DTL, GOI released Rs 55 lakh¹⁸ in March 2001, of which Rs 15 lakh was spent (March 2002) for construction of additional buildings and Rs 26.61 lakh paid (March 2002) to Hospital Services Consultancy Corporation, New Delhi (HSCC) for purchase of machinery and equipment. The balance Rs 13.39 lakh was retained by the Department. The machinery and equipment had

¹⁷ indicating percentage/quantity of ingredients of a particular drug

¹⁸ Construction of additional buildings (Rs 15 lakh), Purchase of machinery and equipment (Rs 30 lakh) and for contractual manpower (Rs 10 lakh)

not been received¹⁹ as of September 2003 except for two items valued Rs 0.39 lakh.

Thus, the objective of strengthening the DTL had not been achieved even after a lapse of two years.

3.1.6 Training

No training programmes conducted for DIs and other staff

Licensing, inspections and investigations are important regulatory functions²⁰ through which the Act is implemented and these functions require knowledgeable and trained Officers/Staff. However, the DCA had not conducted any training programmes to DIs and other officials, except imparting training to three Junior Analysts during 1998-2003. The ADG, DCA, stated (April 2003) that no proposals were submitted for conducting training programmes without however, indicating the reasons.

Inaction of the ADG in organising training programmes to DIs, etc could have adversely affected efficient and effective functioning of the DCA.

3.1.7 Monitoring

Monitoring at State level was very poor

Though the State Government was going ahead with the computerisation in all the departments the DCA had not developed any database of manufacturers/sale concerns/licensees/management information system, monitoring system modules for drug control functions, laboratory functions and licensing functions; except holding the quarterly periodical meetings with the field staff. This indicated the ineffective handling of the affairs of the DCA by the ADG.

The State Drugs Advisory Committee met only once in January 2002. Thus there was no proper monitoring on the implementation of the Act and Rules in the State.

3.1.8 Conclusions

Implementation of the Drugs and Cosmetics Act has been ineffective in the State mainly due to shortage of enforcement staff and insufficient budget provision. The system of licensing and renewal thereof was not fool-proof. There were huge shortfalls in inspection of units. No norms were fixed for sampling of the drugs. Even drugs which were found to be spurious and “not of standard quality” were dealt with in routine fashion leading to pendency of high

¹⁹ due to some constraints in payment of Customs Duty on imported equipment viz., High Performance Thin Layer Chromatography system, Gas Liquid Chromatography, Moisture Balance, Electronic balance and Micro balance

²⁰ involving intelligence, detection, investigation, preparing and filing of complaints, etc. updation of technical matters and court procedures

number of prosecution cases in courts for years. No communication network was in place for dissemination and sharing of information on movement of spurious drugs and persons involved in such activity.


3.1.9 Recommendations

- The Act needs to be amended to prescribe the time schedule for disposal of renewal applications by the DCA.
- The Act also needs to be amended to bring the selling units of Ayurvedic medicines and Cosmetics also under the purview of the Drugs and Cosmetics Act, 1940 to ensure quality.
- There is a need to amend the Act to make all the offences under it as cognizable.
- Each manufacturing/selling unit should be inspected at least twice a year to have proper control.
- Special courts should be established for speedy disposal of cases.
- More enforcement and analytical staff are needed to be acquainted with the latest techniques and legal matters.
- Deterrent penalty should be imposed for manufacture or sale of adulterated/spurious or mis-branded drugs.
- DTL should be strengthened so as to cope up with the requirement of the large number of testing of samples.

The above points were referred to Government in June 2003; reply had not been received (November 2003).

Appendix XXV
(Reference to paragraph 3.1.2 page 36)

Organisation set up of Drugs Control Administration



Appendix XXVI
(Reference to paragraph 3.1.4 II (i) (b) page 40)

A. Shortfalls in inspections by Drugs Inspectors

S.No.	Name of the office	Number of units	Inspections to be conducted	Inspections Conducted	Shortfall	Percentage
1998-99						
1.	Amalapuram	480	960	513	447	47
2.	Anakapalli	428	856	513	343	40
3.	Chittoor	529	1058	451	607	57
4.	Cuddapah	325	650	412	238	37
5.	Guntur	580	1160	526	634	55
6.	Jagityal	424	848	603	245	29
7.	Kakinada	849	1698	548	1150	68
8.	Karimnagar	472	944	456	488	52
9.	Machilipatnam	606	1212	595	617	51
10.	Mahaboobnagar	478	956	393	563	59
11.	Narasaraopeta	385	770	557	213	28
12.	Nizamabad	286	572	492	80	14
13.	Proddatur	283	566	383	183	32
14.	Rajahmundry	438	876	553	323	37
15.	Tenali	488	976	517	459	47
16.	Tirupati	449	898	391	507	56
17.	Vijayawada-I	624	1248	561	687	55
18.	Vijayawada-II	519	1038	472	566	55
19.	Visakhapatnam	453	906	492	414	46
20.	Warangal (R)	288	576	551	25	4
21.	Warangal (U)	379	758	548	210	28
1999-2000						
1.	Amalapuram	482	964	523	441	46
2.	Anakapalli	475	950	599	351	37
3.	Chittoor	561	1122	534	588	52
4.	Cuddapah	354	708	398	310	44
5.	Guntur	682	1364	608	756	55
6.	Jagityal	461	922	603	319	35
7.	Kakinada	969	1938	552	1386	72
8.	Karimnagar	504	1008	348	660	65
9.	Machilipatnam	649	1298	615	683	53
10.	Mahaboobnagar	533	1066	373	693	65
11.	Narasaraopeta	455	910	625	285	31
12.	Nizamabad	322	644	501	143	22
13.	Proddatur	316	632	419	213	34
14.	Rajahmundry	523	1046	616	430	38
15.	Tenali	533	1066	575	491	46
16.	Tirupati	511	1022	447	575	56
17.	Vijayawada-I	650	1300	644	656	50
18.	Vijayawada-II	572	1144	379	765	67
19.	Visakhapatnam	480	960	521	439	46
20.	Warangal (R)	332	664	511	153	23
21.	Warangal (U)	477	954	415	539	56
2000-01						
1.	Amalapuram	545	1090	594	496	45
2.	Anakapalli	568	1136	635	501	44
3.	Chittoor	601	1202	470	732	61
4.	Cuddapah	395	790	313	477	60
5.	Guntur	772	1544	549	995	64
6.	Jagityal	524	1048	647	401	38
7.	Kakinada	1054	2108	584	1524	72
8.	Karimnagar	573	1146	460	686	60
9.	Machilipatnam	688	1376	597	779	57

10.	Mahaboobnagar	592	1184	400	784	66
11.	Narasaraopeta	546	1092	554	538	49
12.	Nizamabad	376	752	509	243	32
13.	Proddatur	349	698	410	285	41
14.	Rajahmundry	599	1198	697	501	42
15.	Tenali	571	1142	476	666	58
16.	Tirupati	600	1200	543	657	55
17.	Vijayawada-I	705	1410	576	834	59
18.	Vijayawada-II	648	1296	725	571	44
19.	Visakhapatnam	518	1036	550	486	47
20.	Warangal (R)	377	754	631	123	16
21.	Warangal (U)	527	1054	566	488	46
2001-02						
1.	Amalapuram	552	552	577	--	--
2.	Anakapalli	659	659	496	163	25
3.	Chittoor	630	630	490	140	22
4.	Cuddapah	422	422	381	41	10
5.	Guntur	883	883	490	393	44
6.	Jagityal	619	619	521	98	16
7.	Kakinada	1214	1214	642	572	47
8.	Karimnagar	649	649	387	262	40
9.	Machilipatnam	722	722	517	205	28
10.	Mahaboobnagar	679	679	469	21	3
11.	Narasaraopeta	629	629	462	167	26
12.	Nizamabad	445	445	495	--	--
13.	Proddatur	385	385	420	--	--
14.	Rajahmundry	688	688	544	144	21
15.	Tenali	598	598	436	162	27
16.	Tirupati	635	635	520	115	18
17.	Vijayawada-I	717	717	561	156	22
18.	Vijayawada-II	759	759	530	229	30
19.	Visakhapatnam	562	562	427	135	24
20.	Warangal (R)	391	391	406	--	--
21.	Warangal (U)	602	602	587	15	2
2002-03						
1.	Amalapuram	577	577	587	--	--
2.	Anakapalli	695	695	638	57	8
3.	Chittoor	643	643	520	123	19
4.	Cuddapah	473	473	428	45	9
5.	Guntur	981	981	590	391	40
6.	Jagityal	670	670	613	57	8
7.	Kakinada	1289	1289	610	679	53
8.	Karimnagar	683	683	492	191	28
9.	Machilipatnam	778	778	610	168	22
10.	Mahaboobnagar	725	725	571	154	21
11.	Narasaraopeta	665	665	532	133	20
12.	Nizamabad	523	523	501	22	4
13.	Proddatur	413	413	360	53	13
14.	Rajahmundry	745	775	578	197	25
15.	Tenali	628	628	437	191	30
16.	Tirupati	687	687	527	160	23
17.	Vijayawada-I	749	749	600	149	20
18.	Vijayawada-II	850	850	558	292	24
19.	Visakhapatnam	609	609	535	74	12
20.	Warangal (R)	351	351	544	--	--
21.	Warangal (U)	644	644	621	23	3

B. Shortfalls in inspections – Regional Offices

Office of the Regional Assistant Director	Number of Inspections			Shortfall (Percentage)
	Units	To be conducted	Conducted	
1998-99				
Warangal	2685	5370	3431	1939 (36)
Cuddapah	3337	6674	3185	3489 (52)
Vijayawada	3740	7480	2827	4653 (62)
Rajahmundry	6404	12808	4726	8082 (63)
Hyderabad (OTC)	2696	5392	4264	1128 (21)
Hyderabad (TC)	2161	4322	2289	2033 (47)
1999-2000				
Warangal	3102	6204	3189	3015 (49)
Cuddapah	3600	7200	3352	3848 (53)
Vijayawada	5127	10254	2614	7640 (74)
Rajahmundry	6417	12834	5078	7756 (60)
Hyderabad (OTC)	3229	6458	4410	2048 (32)
Hyderabad (TC)	2714	5428	2786	2642 (49)
2000-01				
Warangal	3233	6466	3539	2927 (45)
Cuddapah	3855	7710	3250	4460 (58)
Vijayawada	5908	11816	2455	9361 (79)
Rajahmundry	7002	14004	5258	8746 (62)
Hyderabad (OTC)	3672	7344	4630	2714 (37)
Hyderabad (TC)	3199	6398	2429	3969 (62)
2001-02				
Warangal	3678	3678	3084	594 (16)
Cuddapah	4123	4123	3685	438 (11)
Vijayawada	6984	6984	2850	4134 (59)
Rajahmundry	7768	7768	4958	2810 (36)
Hyderabad (OTC)	4117	4117	4446	--
Hyderabad (TC)	3721	3721	2235	1486 (40)
2002-03				
Warangal*	3891	3891	3640	251 (6)
Cuddapah*	4351	4351	3121	1230 (28)
Vijayawada*	7592	7592	2302	5290 (70)
Rajahmundry ^s	8354	8354	4178	4176 (50)
Hyderabad ^s (OTC)	4691	4691	5203	--
Hyderabad (TC) upto March 2003	4027	4027	2984	1043 (26)

* Upto December 2002

\$ Upto February 2003

Appendix XXVII
(Reference to paragraph 3.1.4 II (i) (b) page 40)

Statement showing the variations between figures furnished by Additional Director General, Drugs Control Administration (ADG, DCA) and Regional Assistant Directors

Year	Number of licenced units			Number of Inspections conducted		
	ADG, DCA	Regional Assistant Directors	Variation	ADG, DCA	Regional Assistant Directors	Variation
1998-99	34258	21023	13235	23399	20722	2677
1999-2000	37019	24189	12830	24569	21429	3140
2000-01	29931	26869	3062	24729	21561	3168
2001-02	33202	30391	2811	23367	21258	2109
2002-03	32703	32906	(-) 203	27836	21428*	6408

* Figures as on December 2002 (3 regions), February 2003 (2 regions) and March 2003 (one region)

Implementation of Drugs and Cosmetics Act, 1940

ACB	: Anti Corruption Bureau
ADG, DCA	: Additional Director General, Drugs & Copyright, Drugs Control Administration
ADs	: Regional Assistant Directors
D&C Rules	: Drugs and Cosmetics Rules, 1945
DCA	: Drugs Control Administration
DCLs	: Drugs Control Laboratories
DIs	: Drugs Inspectors
DTL	: Drugs Testing Laboratory
HSCC	: Hospital Services Consultancy Corporation
IEC	: Information, Education and Communication
NPPA	: National Pharmaceutical Pricing Authority
NSQ	: Not of Standard Quality
PAC	: Public Accounts Committee
R&D	: Research and Development
TA	: Travelling Allowance
TB	: Tuberculosis

Prevention and control of fire

ADFO	: Assistant Divisional Fire Officer
APGENCO	: Generation Corporation of Andhra Pradesh Limited
APPHC	: AP Police Housing Corporation
APSRTC	: AP State Road Transport Corporation
DFO	: Divisional Fire Officer
DGFS	: Director General of Fire Services
DO	: Driver Operator
EFC	: Eleventh Finance Commission
GOI	: Government of India
HUDA	: Hyderabad Urban Development Authority
LF	: Leading Firemen
MCH	: Municipal Corporation of Hyderabad
MSBs	: Multi Storied Buildings
NOC	: No Objection Certificate